We are live on ! Find out more
TCM

Tybourne Capital Management Portfolio holdings

AUM $30.9M
1-Year Est. Return 20.1%
This Fund
S&P 500
This Quarter Est. Return
+29.73%
1 Year Est. Return
+20.1%
3 Year Est. Return
+108.99%
5 Year Est. Return
+80.28%
10 Year Est. Return
+751.59%
AUM
$30.9M
AUM Growth
-$3.61M
Cap. Flow
-$10.9M
Cap. Flow %
-35.2%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
2
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
BCYC
Bicycle Therapeutics
BCYC
+$6.91M
2
MBUU icon
Malibu Boats
MBUU
+$2.09M
3
TSHA icon
Taysha Gene Therapies
TSHA
+$1.12M
4
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$775K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Consumer Discretionary 0%

No holdings matched the selected filter criteria.

Similar funds

VM
Valinor Management New York $32.2M AUM 44.16% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
NC
Nucleo Capital Sao Paulo, Sp, Brazil $29.1M AUM 59.16% 1-Year Est. Return
PIM
Pinnacle Investment Management Hong Kong $28.9M AUM 32% 1-Year Est. Return
BCA
Burren Capital Advisors Gibraltar $33M AUM 47.67% 1-Year Est. Return
NCPI
NewView Capital Partners I Burlingame, California $28M AUM 10.55% 1-Year Est. Return
RE
ROB Exploration New York $27.3M AUM 13.99% 1-Year Est. Return
AECF
Annie E. Casey Foundation Baltimore, Maryland $35.2M AUM 35.05% 1-Year Est. Return

Tybourne Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Tybourne Capital Management held 6 positions worth $30.9M, down 10% from $34.5M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Tybourne Capital Management withdrew a net $10.9M in Q3 2025, closing 2 positions and reducing 2 holdings. Its most notable exit was Bicycle Therapeutics, an estimated $6.91M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 94% a quarter earlier, followed by Consumer Discretionary.

  • Tybourne Capital Management's biggest Q3 2025 reduction was Taysha Gene Therapies, cutting an estimated $1.12M.
  • Tybourne Capital Management fully exited Bicycle Therapeutics in Q3 2025, selling an estimated $6.91M.
  • Tybourne Capital Management's ten largest holdings make up 100% of its $30.9M portfolio in Q3 2025.
  • Tybourne Capital Management opened 0 new positions and closed 2 in Q3 2025.
  • Tybourne Capital Management's portfolio value fell 10% quarter-over-quarter to $30.9M.

Based on Tybourne Capital Management's 13F filing for Q3 2025, filed 6 Nov 2025.